JP2019506367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506367A5 JP2019506367A5 JP2018529633A JP2018529633A JP2019506367A5 JP 2019506367 A5 JP2019506367 A5 JP 2019506367A5 JP 2018529633 A JP2018529633 A JP 2018529633A JP 2018529633 A JP2018529633 A JP 2018529633A JP 2019506367 A5 JP2019506367 A5 JP 2019506367A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- modulator
- oxy
- pain
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 59
- 125000005843 halogen group Chemical group 0.000 claims description 51
- 208000002193 Pain Diseases 0.000 claims description 44
- 230000036407 pain Effects 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 208000004296 neuralgia Diseases 0.000 claims description 12
- 208000021722 neuropathic pain Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- -1 R 24 Chemical compound 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
- SKXPEZRPXUSJHY-IKJXHCRLSA-N (5r)-5-ethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 SKXPEZRPXUSJHY-IKJXHCRLSA-N 0.000 claims description 4
- XYISZEPLGKRZAR-NYRJJRHWSA-N (5r)-5-ethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 XYISZEPLGKRZAR-NYRJJRHWSA-N 0.000 claims description 4
- BLJABDKRDIIYLJ-UHFFFAOYSA-N 3-[6-[(3-tert-butyl-1,3-dihydro-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5,5-dimethylimidazolidine-2,4-dione Chemical compound C1=C2C(C(C)(C)C)OCC2=CC=C1OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O BLJABDKRDIIYLJ-UHFFFAOYSA-N 0.000 claims description 4
- PFWPHOLELOXFFV-UHFFFAOYSA-N 5,5-dimethyl-3-[2-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 PFWPHOLELOXFFV-UHFFFAOYSA-N 0.000 claims description 4
- NKMHTNGMJVHRTM-UHFFFAOYSA-N 5,5-dimethyl-3-[6-[[3-methyl-3-(trifluoromethyl)-1h-2-benzofuran-5-yl]oxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C(F)(F)F)C2=C1 NKMHTNGMJVHRTM-UHFFFAOYSA-N 0.000 claims description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- MCSCOJJHSDROQX-QGZVFWFLSA-N (5r)-3-[2-[(2,2-difluoro-7-methyl-1,3-benzodioxol-4-yl)oxy]pyrimidin-5-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical class O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1OC(F)(F)O2 MCSCOJJHSDROQX-QGZVFWFLSA-N 0.000 claims description 2
- SHSPZEJVBTZRAQ-OAQYLSRUSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethyl-5-methylimidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C)C2=C1 SHSPZEJVBTZRAQ-OAQYLSRUSA-N 0.000 claims description 2
- OWZHSHKAPQCKHB-MRXNPFEDSA-N (5r)-3-[6-[(3,3-dimethyl-1h-2-benzofuran-5-yl)oxy]pyridin-3-yl]-5-ethylimidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC2(C)C)C2=C1 OWZHSHKAPQCKHB-MRXNPFEDSA-N 0.000 claims description 2
- LSOZZXGDMKCFRV-MRXNPFEDSA-N (5r)-5-ethyl-3-(2-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyrimidin-5-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(COC23CCC3)C2=C1 LSOZZXGDMKCFRV-MRXNPFEDSA-N 0.000 claims description 2
- GANVXLQPVDRZDP-QGZVFWFLSA-N (5r)-5-ethyl-3-(6-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCC3)C2=C1 GANVXLQPVDRZDP-QGZVFWFLSA-N 0.000 claims description 2
- LWGBRPAONSBLOJ-CYBMUJFWSA-N (5r)-5-ethyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 LWGBRPAONSBLOJ-CYBMUJFWSA-N 0.000 claims description 2
- AMAOXEGBJHLCSF-CQSZACIVSA-N (5r)-5-ethyl-3-[6-(3-methoxy-4-methylphenoxy)pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC)=C1 AMAOXEGBJHLCSF-CQSZACIVSA-N 0.000 claims description 2
- NPNNMBCPDXXEAG-CQSZACIVSA-N (5r)-5-ethyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 NPNNMBCPDXXEAG-CQSZACIVSA-N 0.000 claims description 2
- JFNGOQQEZATLIZ-CYBMUJFWSA-N (5r)-5-ethyl-3-[6-[4-methyl-3-(trifluoromethoxy)phenoxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@@H](CC)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C(OC(F)(F)F)=C1 JFNGOQQEZATLIZ-CYBMUJFWSA-N 0.000 claims description 2
- VJORKOHZKOIAOJ-HXUWFJFHSA-N (5r)-5-ethyl-5-methyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 VJORKOHZKOIAOJ-HXUWFJFHSA-N 0.000 claims description 2
- OYFGQTVERWVDGF-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[2-[(3,3,7-trimethyl-2h-1-benzofuran-4-yl)oxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C2=C1C(C)(C)CO2 OYFGQTVERWVDGF-OAQYLSRUSA-N 0.000 claims description 2
- DZJBKKVCXVSFHQ-QGZVFWFLSA-N (5r)-5-ethyl-5-methyl-3-[2-[4-methyl-3-(trifluoromethoxy)phenoxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CN=C1OC1=CC=C(C)C(OC(F)(F)F)=C1 DZJBKKVCXVSFHQ-QGZVFWFLSA-N 0.000 claims description 2
- CWHUKRBJRARMCX-OAQYLSRUSA-N (5r)-5-ethyl-5-methyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O=C1[C@](CC)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 CWHUKRBJRARMCX-OAQYLSRUSA-N 0.000 claims description 2
- QJEJEPKGWPVGQU-UHFFFAOYSA-N 3-methyl-4-(6-spiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=CC2=C1C1(CC1)CO2 QJEJEPKGWPVGQU-UHFFFAOYSA-N 0.000 claims description 2
- SXVVXFKHWPURFB-UHFFFAOYSA-N 3-methyl-4-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]-1h-1,2,4-triazol-5-one Chemical compound CC1=NNC(=O)N1C(C=N1)=CC=C1OC1=CC=C(C)C2=C1C1(CC1)CO2 SXVVXFKHWPURFB-UHFFFAOYSA-N 0.000 claims description 2
- ABBBYWZTLYAUOM-UHFFFAOYSA-N 5,5-dimethyl-3-(6-spiro[1h-2-benzofuran-3,1'-cyclobutane]-5-yloxypyridin-3-yl)imidazolidine-2,4-dione Chemical compound O=C1C(C)(C)NC(=O)N1C(C=N1)=CC=C1OC1=CC=C(COC23CCC3)C2=C1 ABBBYWZTLYAUOM-UHFFFAOYSA-N 0.000 claims description 2
- JYHHQTRVJFMEGR-UHFFFAOYSA-N 5,5-dimethyl-3-[2-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound O1CC2(CC2)C2=C1C(C)=CC=C2OC(N=C1)=NC=C1N1C(=O)NC(C)(C)C1=O JYHHQTRVJFMEGR-UHFFFAOYSA-N 0.000 claims description 2
- RKJVNBMHIUOWSI-UHFFFAOYSA-N 5,5-dimethyl-3-[2-[4-methyl-3-(trifluoromethoxy)phenoxy]pyrimidin-5-yl]imidazolidine-2,4-dione Chemical compound C1=C(OC(F)(F)F)C(C)=CC=C1OC1=NC=C(N2C(C(C)(C)NC2=O)=O)C=N1 RKJVNBMHIUOWSI-UHFFFAOYSA-N 0.000 claims description 2
- FTJZGRAFIVZFDZ-UHFFFAOYSA-N 5,5-dimethyl-3-[6-(7-methylspiro[2h-1-benzofuran-3,1'-cyclopropane]-4-yl)oxypyridin-3-yl]imidazolidine-2,4-dione Chemical compound O1CC2(CC2)C2=C1C(C)=CC=C2OC(N=C1)=CC=C1N1C(=O)NC(C)(C)C1=O FTJZGRAFIVZFDZ-UHFFFAOYSA-N 0.000 claims description 2
- VXCFTYWNOQFXHH-UHFFFAOYSA-N 5,5-dimethyl-3-[6-[4-methyl-3-(trifluoromethoxy)phenoxy]pyridin-3-yl]imidazolidine-2,4-dione Chemical compound C1=C(OC(F)(F)F)C(C)=CC=C1OC1=CC=C(N2C(C(C)(C)NC2=O)=O)C=N1 VXCFTYWNOQFXHH-UHFFFAOYSA-N 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- PXFIECRVZMWQOW-UHFFFAOYSA-N CC1=C(C=C(C=C1)OC1=NC=C(C=N1)N1C(NC(C1)=O)=O)OC(F)(F)F Chemical compound CC1=C(C=C(C=C1)OC1=NC=C(C=N1)N1C(NC(C1)=O)=O)OC(F)(F)F PXFIECRVZMWQOW-UHFFFAOYSA-N 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 238000002266 amputation Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960002870 gabapentin Drugs 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229940124583 pain medication Drugs 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 2
- 229960001233 pregabalin Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 0 CN(CNC1(*)*)C1=O Chemical compound CN(CNC1(*)*)C1=O 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N COc1ccccc1 Chemical compound COc1ccccc1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022106247A JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2024154042A JP2025003958A (ja) | 2015-12-10 | 2024-09-06 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1521751.6 | 2015-12-10 | ||
| GBGB1521751.6A GB201521751D0 (en) | 2015-12-10 | 2015-12-10 | Novel uses |
| PCT/GB2016/053879 WO2017098254A1 (en) | 2015-12-10 | 2016-12-09 | Modulators of kv3 channels to treat pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106247A Division JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506367A JP2019506367A (ja) | 2019-03-07 |
| JP2019506367A5 true JP2019506367A5 (cg-RX-API-DMAC7.html) | 2020-01-30 |
| JP7149847B2 JP7149847B2 (ja) | 2022-10-07 |
Family
ID=55274489
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529633A Active JP7149847B2 (ja) | 2015-12-10 | 2016-12-09 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2022106247A Pending JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2024154042A Pending JP2025003958A (ja) | 2015-12-10 | 2024-09-06 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106247A Pending JP2022141699A (ja) | 2015-12-10 | 2022-06-30 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
| JP2024154042A Pending JP2025003958A (ja) | 2015-12-10 | 2024-09-06 | 疼痛を治療するためのｋｖ３チャネルのモジュレーター |
Country Status (21)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| AR116713A1 (es) | 2018-10-16 | 2021-06-02 | Autifony Therapeutics Ltd | COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 |
| US20200131156A1 (en) * | 2018-10-30 | 2020-04-30 | H. Lundbeck A/S | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS |
| IL311021A (en) | 2018-11-30 | 2024-04-01 | Otsuka Pharma Co Ltd | Heterocyclic compounds for the treatment of epilepsy |
| JP7522203B2 (ja) | 2020-02-06 | 2024-07-24 | アウトイフオンイ トヘラペウトイクス リミテッド | Ｋｖ３モジュレーター |
| IL310160A (en) | 2021-08-10 | 2024-03-01 | Autifony Therapeutics Ltd | potassium channel modulators |
| CN113788741B (zh) * | 2021-09-28 | 2023-12-29 | 大连九信精细化工有限公司 | 一种制备2-环丙基苯酚衍生物的方法 |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201001855A1 (ru) | 2008-06-06 | 2011-08-30 | Юсб Фарма, С.А. | Соединения, содержащие циклобутоксигруппу |
| ES2575215T3 (es) * | 2009-12-11 | 2016-06-27 | Autifony Therapeutics Limited | Derivados de imidazolidindiona |
| WO2012076877A1 (en) * | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| CN103596943B (zh) | 2011-06-07 | 2016-10-12 | 奥蒂福尼疗法有限公司 | 用作kv3抑制剂的乙内酰脲衍生物 |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| CA2856654C (en) * | 2011-12-06 | 2020-03-31 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| US9669030B2 (en) | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
| BR112014028991A2 (pt) * | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | triazóis como inibidores de kv3 |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
-
2015
- 2015-12-10 GB GBGB1521751.6A patent/GB201521751D0/en not_active Ceased
-
2016
- 2016-12-09 PL PL16813020.1T patent/PL3386506T3/pl unknown
- 2016-12-09 EP EP16813020.1A patent/EP3386506B1/en active Active
- 2016-12-09 JP JP2018529633A patent/JP7149847B2/ja active Active
- 2016-12-09 ES ES16813020T patent/ES2974902T3/es active Active
- 2016-12-09 EA EA201891377A patent/EA038059B1/ru unknown
- 2016-12-09 AU AU2016367239A patent/AU2016367239B2/en active Active
- 2016-12-09 MX MX2018007074A patent/MX385578B/es unknown
- 2016-12-09 CA CA3005302A patent/CA3005302A1/en active Pending
- 2016-12-09 HU HUE16813020A patent/HUE066879T2/hu unknown
- 2016-12-09 KR KR1020187017088A patent/KR102812887B1/ko active Active
- 2016-12-09 PT PT168130201T patent/PT3386506T/pt unknown
- 2016-12-09 DK DK16813020.1T patent/DK3386506T3/da active
- 2016-12-09 US US16/060,714 patent/US11147813B2/en active Active
- 2016-12-09 SG SG11201804123VA patent/SG11201804123VA/en unknown
- 2016-12-09 CN CN202410102663.8A patent/CN118267386A/zh active Pending
- 2016-12-09 HR HRP20240497TT patent/HRP20240497T1/hr unknown
- 2016-12-09 CN CN201680072639.8A patent/CN108472288B/zh active Active
- 2016-12-09 FI FIEP16813020.1T patent/FI3386506T3/fi active
- 2016-12-09 WO PCT/GB2016/053879 patent/WO2017098254A1/en not_active Ceased
- 2016-12-09 BR BR112018011700-5A patent/BR112018011700B1/pt active IP Right Grant
-
2018
- 2018-05-30 IL IL259717A patent/IL259717B/en active IP Right Grant
-
2021
- 2021-09-10 US US17/472,493 patent/US11944623B2/en active Active
-
2022
- 2022-06-30 JP JP2022106247A patent/JP2022141699A/ja active Pending
-
2024
- 2024-01-30 US US18/427,639 patent/US20250017925A1/en active Pending
- 2024-09-06 JP JP2024154042A patent/JP2025003958A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506367A5 (cg-RX-API-DMAC7.html) | ||
| JP6162144B2 (ja) | ４，４−二置換−１，４−ジヒドロピリミジン、及びｂ型肝炎の処置のための医薬としてのその使用 | |
| HRP20240497T1 (hr) | Modulatori kv3 kanala za liječenje boli | |
| JP5702138B2 (ja) | 過剰増殖障害および血管新生に関連する疾患の処置に有用なヘテロアリール置換ピラゾール誘導体 | |
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| JP6385954B2 (ja) | キナーゼ調節のための化合物および方法、ならびにその適応 | |
| US9290507B2 (en) | B-RAF kinase inhibitors | |
| US11292786B2 (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| JP2011503166A5 (cg-RX-API-DMAC7.html) | ||
| JP6195684B2 (ja) | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 | |
| JP2016523911A5 (cg-RX-API-DMAC7.html) | ||
| JP2014516073A5 (cg-RX-API-DMAC7.html) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2015520764A5 (cg-RX-API-DMAC7.html) | ||
| JP2016145215A5 (cg-RX-API-DMAC7.html) | ||
| JP2013544873A5 (cg-RX-API-DMAC7.html) | ||
| WO2013057101A1 (de) | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer | |
| WO2015002994A2 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| JP2013514973A (ja) | チロシンキナーゼ阻害剤 | |
| US20130225562A1 (en) | Pyridyltriazoles | |
| WO2011141326A1 (de) | Substituierte heterocyclylbenzyl-pyrazole und ihre verwendung | |
| JP6154804B2 (ja) | アミドピリジン誘導体およびその用途 | |
| WO2019107386A1 (ja) | 抗腫瘍剤 | |
| US20180243298A1 (en) | Trpv3 modulators |